transdermal delivery system


Also found in: Dictionary, Thesaurus, Encyclopedia.

transdermal delivery system,

n a method of applying a drug to unbroken skin. The drug is absorbed through the skin and enters the body's systems. It is used particularly for the administration of nitroglycerin and in nicotine patches used to assist individuals to withdraw from the use of tobacco.
References in periodicals archive ?
to develop and commercialize a transdermal patch for delivering enoxaparin sodium (currently marketed as Lovenox[R]) utilizing the PassPort[R] Transdermal Delivery System.
Altea Therapeutics is the recipient of the Frost & Sullivan 2007 Technology Innovation Award for its development of the PassPort Transdermal Delivery System and was named one of the top 50 technology companies in the Southeast of the U.
Under the terms of the agreement, Altea Therapeutics has granted Lilly and Amylin exclusive worldwide rights to develop and commercialize transdermal exenatide utilizing the Altea Therapeutics proprietary PassPort[R] Transdermal Delivery System.
Transdermal delivery systems like Estrasorb's have an advantage over oral delivery systems because of the lack of the first-pass hepatic effect, which causes high peaks and troughs in blood levels of the delivered drug.
While many of Ciba-Geigy's top-selling drugs were launched a generation ago, the company has successfully defended its turf in areas where patents have expired by reducing dosage sizes for over-the-counter sales and launching innovative, transdermal delivery systems.
Working in collaboration with patients and their physicians, Pharmaca pharmacists can change the strength of a medication, alter its form so it is easier to ingest or add flavor to make it more pleasant-tasting, Unique dosage forms include transdermal delivery systems, troches, suppositories and veterinary applications.
Because of their ease-of-use and dosing characteristics, drug developers are continuing to turn to transdermal delivery systems for HRT products.
Our expertise in such areas as cardiovascular conditions and the central nervous system, in transdermal delivery systems, and in the generic drug business puts us in an enviable position.
In addition to the handful of FDA-approved transdermal CNS products, more than a dozen companies are currently pursuing a range of APIs in transdermal delivery systems that target neurological and CNS conditions.
In addition, the future is bound to witness advancements in protein delivery through oral, nasal, buccal, pulmonary and transdermal delivery systems.